Acer Therapeutics Inc., a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
Previous Symbol
CUSIPN/A
Phone844-902-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio22.01
Quick Ratio22.01
Price-To-Earnings
Trailing P/E Ratio-4.66
Forward P/E Ratio-8.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.90 million
Price / Sales59.93
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.03 per share
Price / Book5.90
Profitability
EPS (Most Recent Fiscal Year)($3.84)
Net Income$-14,190,000.00
Net MarginsN/A
Return on Equity-62.94%
Return on Assets-57.90%
Miscellaneous
Employees6
Outstanding Shares9,720,000
Market Cap$173.78 million
OptionableNot Optionable
Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions
What is Acer Therapeutics' stock symbol?
Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
How were Acer Therapeutics' earnings last quarter?
Acer Therapeutics Inc (NASDAQ:ACER) announced its quarterly earnings data on Monday, November, 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.10. View Acer Therapeutics' Earnings History.
When is Acer Therapeutics' next earnings date?
What price target have analysts set for ACER?
4 brokerages have issued 1-year price targets for Acer Therapeutics' shares. Their predictions range from $46.00 to $70.00. On average, they anticipate Acer Therapeutics' share price to reach $57.00 in the next year. This suggests a possible upside of 218.8% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.
What is the consensus analysts' recommendation for Acer Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acer Therapeutics.
What are Wall Street analysts saying about Acer Therapeutics stock?
Here are some recent quotes from research analysts about Acer Therapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We value Acer using a composite risk-adjusted net present value (rNPV) approach, which employs a 15% discount rate and 30% effective tax rate across all future cash flows, while ascribing an 85% probability of success to EDSIVO and a 60% and 50% probability of success to MSUD, respectively. This yields a total rNPV of $600M, with $355M coming from EDSIVO and $250M from ACER-001. Assuming approximately 11M fully-diluted shares outstanding as of mid-2019, this translates into a price objective of $55.00 per share." (12/5/2018)
- 2. According to Zacks Investment Research, "Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. " (11/14/2018)
Has Acer Therapeutics been receiving favorable news coverage?
Headlines about ACER stock have trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are some of Acer Therapeutics' key competitors?
Some companies that are related to Acer Therapeutics include Principia Biopharma (PRNB), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), Rocket Pharmaceuticals (RCKT), Eagle Pharmaceuticals (EGRX), Omeros (OMER), Viking Therapeutics (VKTX), Inflarx (IFRX), ANI Pharmaceuticals (ANIP), Vectura Group (VEGPF), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Eidos Therapeutics (EIDX), Karyopharm Therapeutics (KPTI) and AMAG Pharmaceuticals (AMAG).
Who are Acer Therapeutics' key executives?
Acer Therapeutics' management team includes the folowing people:
- Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 42)
- Mr. Harry S. Palmin, COO & CFO (Age 48)
- Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 53)
- Mr. Jefferson Davis, Acting Chief Bus. Officer (Age 51)
- Ms. Kim Tharaldsen, Sr. Director of Marketing
Who are Acer Therapeutics' major shareholders?
Acer Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vivo Capital LLC (5.82%), Vanguard Group Inc. (2.51%), Vanguard Group Inc (2.51%), Heartland Advisors Inc. (2.16%), Emerald Mutual Fund Advisers Trust (1.29%) and EAM Investors LLC (0.22%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.
Which institutional investors are buying Acer Therapeutics stock?
ACER stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Vanguard Group Inc, Vanguard Group Inc., Emerald Mutual Fund Advisers Trust, Heartland Advisors Inc., EAM Investors LLC, Monashee Investment Management LLC and Renaissance Technologies LLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.
How do I buy shares of Acer Therapeutics?
Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acer Therapeutics' stock price today?
One share of ACER stock can currently be purchased for approximately $17.88.
How big of a company is Acer Therapeutics?
Acer Therapeutics has a market capitalization of $173.78 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.
What is Acer Therapeutics' official website?
How can I contact Acer Therapeutics?
Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at hans[email protected]
MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
